Replies to post #147924 on Biotech Values

[DewDiligence]

Tevagrastim has only 5% of the G-CSF market in the EU because it's not interchangeable with Neopogen. I expect an even lower penetration for Tevgrastim in the US when it comes to market in late 2013.